Catalyst Wire Dossier Catalyst Wire Dossier

selumetinib (AZD6244)

selumetinib · AstraZeneca
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for selumetinib (AZD6244), covering 2018-06-20 to 2018-06-20. Get the full timeline:

Most recent: Clinical Trial Update: AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients [Phase 2]

See pricing